Compelling Case for These Two Large Caps
At these prices, both Apple (AAPL) and Gilead (GILD) look extremely cheap.
GILD is approaching its 50-day and could bounce back strong. Its got a full pipeline and successful drugs that are growing at a very fast clip. Generally, biotechs are riskier, however, Gilead is a large cap with a trail of great quarters. Unless their drugs show signs of being the next Vioxx, this is the one to own for a few years. At under $60, its a bargain.
AAPL might see a little more weakness, but I would buy now and more if it goes down. With the new Intel Mac Mini’s and more content being added to Apple’s video library, this recent 25% correction is overdone.
Faisal Laljee
